AIM ImmunoTech Inc (AIM) has a current Price-to-Book (P/B) ratio of -0.54. Compared to its 3-year average P/B ratio of 1.59, the current P/B ratio is approximately -134.03% higher. Relative to its 5-year average P/B ratio of 1.34, the current P/B ratio is about -140.51% higher. AIM ImmunoTech Inc (AIM) has a Forward Free Cash Flow (FCF) yield of approximately -380.71%. Compared to its 3-year average FCF yield of -132.42%, the current FCF yield is approximately 187.51% lower. Relative to its 5-year average FCF yield of -89.34%, the current FCF yield is about 326.13% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for AIM competitors is 0.00, providing a benchmark for relative valuation. AIM ImmunoTech Inc Corp (AIM.A) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of -25.71%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of AIM increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of AIM in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is AIM currently overvalued or undervalued?

What is AIM ImmunoTech Inc (AIM) fair value?

AIM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of AIM ImmunoTech Inc (AIM) is between NaN to NaN according to relative valuation method.

How does AIM's valuation metrics compare to the industry average?

The average P/S ratio for AIM's competitors is 0.00, providing a benchmark for relative valuation. AIM ImmunoTech Inc Corp (AIM) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of -25.71%, this premium appears unsustainable.

What is the current P/B ratio for AIM ImmunoTech Inc (AIM) as of Mar 03 2026?

As of Mar 03 2026, AIM ImmunoTech Inc (AIM) has a P/B ratio of -0.54. This indicates that the market values AIM at -0.54 times its book value.

What is the current FCF Yield for AIM ImmunoTech Inc (AIM) as of Mar 03 2026?

As of Mar 03 2026, AIM ImmunoTech Inc (AIM) has a FCF Yield of -380.71%. This means that for every dollar of AIM ImmunoTech Inc's market capitalization, the company generates -380.71 cents in free cash flow.

What is the current Forward P/E ratio for AIM ImmunoTech Inc (AIM) as of Mar 03 2026?

As of Mar 03 2026, AIM ImmunoTech Inc (AIM) has a Forward P/E ratio of -0.28. This means the market is willing to pay $-0.28 for every dollar of AIM ImmunoTech Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for AIM ImmunoTech Inc (AIM) as of Mar 03 2026?

As of Mar 03 2026, AIM ImmunoTech Inc (AIM) has a Forward P/S ratio of 0.00. This means the market is valuing AIM at $0.00 for every dollar of expected revenue over the next 12 months.

AIM Valuation